1 Reason I'm Never Selling Novo Nordisk Stock

Over the past two years, investors have sold off Novo Nordisk (NYSE: NVO) stock as it has faced a number of challenges. It has been losing ground in the GLP-1 market, which accounts for most of its revenue. Novo Nordisk's 2026 guidance implies that its revenue will decline this year. Despite the headwinds, there are many reasons to remain bullish on the company. Here's one reason why, as a shareholder, I intend to stay put. Image source: Getty Images. Will AI create the world's first trillionaire? Our tea ...